02. November 2008
Meet Zedira at MEDICA in November 2008
Document
01. November 2008
Meet Zedira at BIO-Europe in November 2008
Document
03. September 2008
Sanofi-Aventis names Zedira as supplier for R&D products in September 2008
Document
02. September 2008
Structure of inhibited tissue transglutaminase published at XXth International Symposium on Medicinal Chemistry in September 2008
Document
02. September 2008
What Links Celiac Disease, Thrombosis, Skin and Hair? (Article in lab&more September 2008)
Document
08. August 2008
Novo Nordisk names Zedira as supplier for R&D products in August 2008
Document
03. June 2008
Zedira launches TG6 In Vitro Diagnostic (IVD) in June 2008
Document
01. April 2008
Transglutaminase Newsletter April 2008
Document
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Press release: Zedira announces ISO 9001:2015 certification
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering